Unlocking the enigma: unraveling multiple cognitive dysfunction linked to glymphatic impairment in early Alzheimer's disease.
Alzheimer’s disease
classification
clinical dementia rating scale
cognitive dysfunction
diffusion tensor imaging
glymphatic system
medical image processing
mild cognitive impairment
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
05
2023
accepted:
26
06
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Alzheimer's disease (AD) is one of the world's well-known neurodegenerative diseases, which is related to the balance mechanism of production and clearance of two proteins (amyloid-β and tau) regulated by the glymphatic system. Latest studies have found that AD patients exhibit impairments to their glymphatic system. However, the alterations in the AD disease continuum, especially in the early stages, remain unclear. Moreover, the relationship between the glymphatic system and cognitive dysfunction is still worth exploring. A novel diffusion tensor image analysis method was applied to evaluate the activity of the glymphatic system by an index for diffusivity along the perivascular space (ALPS-index). Based on this method, the activity of the glymphatic system was noninvasively evaluated in 300 subjects, including 111 normal controls (NC), 120 subjects with mild cognitive impairment (MCI), and 69 subjects with AD. Partial correlation analysis was applied to explore the association between glymphatic system and cognitive impairment based on three domain-general scales and several domain-specific cognitive scales. Receiver operating characteristic curve analysis was used to evaluate the classification performance of ALPS-index along the AD continuum. ALPS-index was significantly different among NC, MCI and AD groups, and ALPS-index decreased with cognitive decline. In addition, ALPS-index was significantly correlated with the scores of the clinical scales ( Here, we show that the glymphatic system is closely associated with multiple cognitive dysfunctions, and ALPS-index can be used as a biomarker for alterations along the AD continuum. This may provide new targets and strategies for the treatment of AD, and has the potential to assist clinical diagnosis.
Sections du résumé
Background
UNASSIGNED
Alzheimer's disease (AD) is one of the world's well-known neurodegenerative diseases, which is related to the balance mechanism of production and clearance of two proteins (amyloid-β and tau) regulated by the glymphatic system. Latest studies have found that AD patients exhibit impairments to their glymphatic system. However, the alterations in the AD disease continuum, especially in the early stages, remain unclear. Moreover, the relationship between the glymphatic system and cognitive dysfunction is still worth exploring.
Methods
UNASSIGNED
A novel diffusion tensor image analysis method was applied to evaluate the activity of the glymphatic system by an index for diffusivity along the perivascular space (ALPS-index). Based on this method, the activity of the glymphatic system was noninvasively evaluated in 300 subjects, including 111 normal controls (NC), 120 subjects with mild cognitive impairment (MCI), and 69 subjects with AD. Partial correlation analysis was applied to explore the association between glymphatic system and cognitive impairment based on three domain-general scales and several domain-specific cognitive scales. Receiver operating characteristic curve analysis was used to evaluate the classification performance of ALPS-index along the AD continuum.
Results
UNASSIGNED
ALPS-index was significantly different among NC, MCI and AD groups, and ALPS-index decreased with cognitive decline. In addition, ALPS-index was significantly correlated with the scores of the clinical scales (
Conclusion
UNASSIGNED
Here, we show that the glymphatic system is closely associated with multiple cognitive dysfunctions, and ALPS-index can be used as a biomarker for alterations along the AD continuum. This may provide new targets and strategies for the treatment of AD, and has the potential to assist clinical diagnosis.
Identifiants
pubmed: 37547134
doi: 10.3389/fnins.2023.1222857
pmc: PMC10400773
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1222857Informations de copyright
Copyright © 2023 Zhong, Zhang, Xu, Zheng, Wang, Jiang and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Alzheimers Res Ther. 2020 Oct 2;12(1):125
pubmed: 33008458
Mol Neurodegener. 2015 Nov 02;10:58
pubmed: 26526066
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2163-2173
pubmed: 35032179
Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2113641119
pubmed: 35380901
Radiology. 2018 Sep;288(3):703-709
pubmed: 29737953
Jpn J Radiol. 2017 Apr;35(4):172-178
pubmed: 28197821
Arch Clin Neuropsychol. 2004 Mar;19(2):203-14
pubmed: 15010086
Invest Radiol. 2018 Sep;53(9):529-534
pubmed: 29652699
Psychiatr Pol. 2016 Oct 31;50(5):1039-1052
pubmed: 27992895
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Appl Neuropsychol. 1997;4(4):249-51
pubmed: 16318476
Dement Geriatr Cogn Disord. 2002;13(1):13-20
pubmed: 11731710
Clin Neuropsychol. 1999 Aug;13(3):348-58
pubmed: 10726605
Psychiatry Res. 2013 Sep 30;213(3):249-55
pubmed: 23830931
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Front Aging Neurosci. 2022 Aug 26;14:935652
pubmed: 36092817
Neurology. 1995 May;45(5):883-8
pubmed: 7746401
Neuroimage. 2018 Feb 15;167:104-120
pubmed: 29155184
J Neurosurg. 2017 Mar;126(3):945-971
pubmed: 27257832
Brain Res. 2017 Jan 15;1655:77-89
pubmed: 27867033
Jpn J Radiol. 2022 Feb;40(2):147-158
pubmed: 34390452
Brain. 2020 Aug 1;143(8):2576-2593
pubmed: 32705145
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
Lancet. 2021 Apr 24;397(10284):1577-1590
pubmed: 33667416
Brain Dev. 2005 Dec;27(8):564-9
pubmed: 16310591
Arch Neurol. 2009 Dec;66(12):1447-55
pubmed: 20008648
Science. 2020 Oct 2;370(6512):50-56
pubmed: 33004510
J Magn Reson Imaging. 2020 Jan;51(1):11-24
pubmed: 31423710
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Appl Neuropsychol Adult. 2022 Jan-Feb;29(1):41-52
pubmed: 31881159
Brain. 2021 Oct 22;144(9):2771-2783
pubmed: 33725124
Neurology. 2017 Nov 14;89(20):2031-2038
pubmed: 29046362
Lancet. 2020 Aug 8;396(10248):413-446
pubmed: 32738937
Neuropsychiatr Dis Treat. 2020 Jun 19;16:1543-1554
pubmed: 32606706
Neuron. 2014 Nov 5;84(3):608-22
pubmed: 25442939
J Neuroimaging. 2021 May;31(3):569-578
pubmed: 33556226
Clin Neuropsychol. 2017 Jan;31(1):154-167
pubmed: 27690752
Front Aging Neurosci. 2021 Nov 15;13:773951
pubmed: 34867300
Ageing Res Rev. 2022 Feb;74:101544
pubmed: 34933129
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997300
Science. 2013 Oct 18;342(6156):373-7
pubmed: 24136970
J Alzheimers Dis. 2022;90(1):295-303
pubmed: 36120782
Arch Neurol. 2001 Dec;58(12):1985-92
pubmed: 11735772
AJNR Am J Neuroradiol. 2019 Aug;40(8):1257-1264
pubmed: 31320462
Ann Neurol. 2023 Jan;93(1):164-174
pubmed: 36214568
Biol Psychiatry. 2020 May 1;87(9):808-818
pubmed: 31735253